Sanofi Pasteur Inc.

Connaught Laboratories Limited

Aventis Pasteur Limited

University of Alberta

Other

Aventis Pasteur Limited/aventis Pasteur Limitee

Raymond P Oomen

Andrew D Murdin

Pamela L Dunn

Michel Henri Klein

Sheena M Loosmore

Joe Wang

Pele Chong

Yan-Ping Yang

Glen D Armstrong

Stephen A Cockle

Randy J Read

Bart Hazes

Penelope E Stein

Shi-Xian Cao

Mark Parrington

Neil L Berinstein

Laszlo Radvanyi

Scott Gallichan

Corey Lovitt

Artur Pedyczak

Devender Singh-Sandhu

George A Cates

Michel H Klein

Sonia E Sanhueza

The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.

Tumor antigens BFA4 and BCY1 for prevention and / or treatment of cancer

The present invention provides purified and isolated polynucleotide molecules that encodepolypeptides which can be used in methods to prevent, treat, and diagnoseinfection. In one form of the invention, the polypeptides relate to the 98 KDa OMP antigen designated CPN100686 RY 54 (SEQ ID No:14, encoded in one form by SEQ ID NO:1).

[object Object]

The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of, specifically, employing a vector containing a nucleotide sequence encoding a 98 kDa outer membrane protein of a strain ofand a promoter to effect expression of the 98 kDa outer membrane protein gene in the host. Modifications are possible within the scope of this invention.

The present invention provides vaccines and methods for immunizing a host, including humans, against disease caused by infection by a strain of, specifically. The vaccine and method employ an OMP (outer membrane protein) of a strain of. Modifications are possible within the scope of this invention.

The present invention provides vaccines for immunizing a host, including humans, against disease caused by infection by a strain of, specifically. The vaccine and method employ a full-length, 5'-truncated or 3&#x2032;-truncated 76 kDa protein of a strain of. Modifications are possible within the scope of this invention.

Chlamydia antigens and protein vaccine

The present invention provides vaccines and methods for immunizing a host, including humans, against disease caused by infection by a strain of, specifically. The vaccine and method employ a 60 kDa cysteine-rich membrane protein of a strain of. Modifications are possible within the scope of this invention.

The present invention provides vaccines and methods for immunizing a host, including humans, against disease caused by infection by a strain ofspecificallyThe vaccine and method employ a full-length, 5'-truncated or 3&#x2032;-truncated 76kDa protein of a strain ofModifications are possible within the scope of this invention.

The present invention provides purified and isolated polynucleotide molecules that encodepolypeptides which can be used in methods to prevent, treat, and diagnoseinfection. In one form of the invention, the polynucleotide molecules encode polypeptides CPN100988 RY-68 (SEQ ID Nos:13 and 26).

The present invention provides a method of immunizing a host against disease caused by infection by a strain of, specifically. The method involves nucleic acid immunization, including DNA immunization, and employs a vector containing a nucleotide sequence which encodes an ATP/ADP translocase of a strain of. The nucleotide sequence is operably linked to a promoter to effect expression of the ATP/ADP translocase in the host. The host may be a human host. Modifications are possible within the scope of this invention.

The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of, specificallyemploying a vector containing a nucleotide sequence encoding a 98 kDa outer membrane protein of a strain ofand a promoter to effect expression of the 98 kDa outer membrane protein gene in the host. Modifications are possible within the scope of this invention.

The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of, specifically, employing a vector containing a nucleotide sequence encoding OMP (outer membrane protein) of a strain ofand a promoter to effect expression of the OMP (outer membrane protein) gene in the host. Modifications are possible within the scope of this invention.

Chlamydia antigens and corresponding DNA fragments and uses thereof

The present invention provides purified and isolated polynucleotide molecules that encodepolypeptides which can be used in methods to prevent, treat, and diagnoseinfection. In one form of the invention, the polynucleotide molecules are selected from DNA that encode polypeptides CPN100686 RY 54 (SEQ ID Nos: 1 and 14), CPN100696 RY-55 (SEQ ID Nos: 2 and 15), CPN100709 RY-57 (SEQ ID Nos: 3 and 16), CPN100710 RY-58 (SEQ ID Nos: 4 and 17), CPN100711 RY-59 (SEQ ID Nos: 5 and 18), CPN100877 RY-61 (SEQ ID Nos: 6 and 19), CPN100325 RY-62 (SEQ ID Nos: 7 and 20), CPN100368 RY-63 (SEQ ID Nos: 8 and 21), CPN100624 RY-64 (SEQ ID Nos:9 and 22), CPN100633 RY-65 (SEQ ID Nos:10 and 23), CPN100985 RY-66 (SEQ ID Nos:11 and 24), CPN100987 RY-67 (SEQ ID Nos:12 and 25) and CPN100988 RY-68 (SEQ ID Nos:13 and 26).

The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of, specifically, employing a vector containing a nucleotide sequence encoding a 60 kDa cysteine-rich membrane protein of a strain ofand a promoter to effect expression of the 60 kDa cysteine-rich membrane protein gene in the host. Modifications are possible within the scope of this invention.

Growing community of inventors

Aurora, Canada

Raymond P Oomen